Lung Adenocarcinoma Clinical Trials

44 recruitingLast updated: June 17, 2026

There are 44 actively recruiting lung adenocarcinoma clinical trials across 18 countries. Studies span Phase 2, Not Applicable, Phase 1, Phase 3, Early Phase 1. Top locations include Shanghai, Shanghai Municipality, China, Chicago, Illinois, United States, Los Angeles, California, United States. Updated daily from ClinicalTrials.gov.


Lung Adenocarcinoma Trials at a Glance

44 actively recruiting trials for lung adenocarcinoma are listed on ClinicalTrialsFinder across 6 cities in 18 countries. The largest study group is Phase 2 with 11 trials, with the heaviest enrollment activity in Shanghai, Chicago, and Los Angeles. Lead sponsors running lung adenocarcinoma studies include Fudan University, Shanghai Pulmonary Hospital, Shanghai, China, and Jonsson Comprehensive Cancer Center.

Browse lung adenocarcinoma trials by phase

Treatments under study

About Lung Adenocarcinoma Clinical Trials

Looking for clinical trials for Lung Adenocarcinoma? There are currently 33 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Lung Adenocarcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Lung Adenocarcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 44 trials

Recruiting
Phase 1

CT-95 in Advanced Cancers Associated With Mesothelin Expression

Colorectal, CancerMesothelin-Expressing TumorsEpithelial Ovarian Cancer+8 more
Context Therapeutics Inc.70 enrolled9 locationsNCT06756035
Recruiting
Phase 2

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

Stage III Lung Cancer AJCC v8Lung AdenocarcinomaLung Non-Squamous Non-Small Cell Carcinoma+1 more
National Cancer Institute (NCI)42 enrolled34 locationsNCT05198830
Recruiting

EX VIVO DRUG RESPONSE PROFILING AND OUTCOME PREDICTION IN LUNG ADENOCARCINOMA

Lung AdenocarcinomaMalignant Pleural Effusions (Mpe)
Sheba Medical Center400 enrolled1 locationNCT07636252
Recruiting

Vortioxetine for Cognitive Function in ALK-positive NSCLC Treated With Lorlatinib

Lung AdenocarcinomaDepressionCognitive Dysfunction+3 more
Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo24 enrolled1 locationNCT07633626
Recruiting
Phase 1Phase 2

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

Ovarian CancerEndometrial CancerLung Adenocarcinoma+1 more
AstraZeneca506 enrolled60 locationsNCT05797168
Recruiting

Clinical Application of PET Imaging Targeting MSLN in Malignant Tumors

Pancreatic CancerOvarian CancerLung Adenocarcinoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology100 enrolled1 locationNCT06843629
Recruiting
Phase 2

Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung Adenocarcinoma

Lung Adenocarcinoma
Samsung Medical Center59 enrolled1 locationNCT05528458
Recruiting

Shared Decision Making in Patients With Lung Cancer

SurgeryLung Adenocarcinoma
Sichuan Cancer Hospital and Research Institute190 enrolled1 locationNCT05191485
Recruiting
Phase 1Phase 2

Study of Bemcentinib Plus Pacritinib In Patients With Advanced Lung Adenocarcinoma

Advanced Lung Adenocarcinoma
The University of Texas Health Science Center at San Antonio44 enrolled1 locationNCT06516887
Recruiting

Pathogenic Variants in Genes Associated With Lung Adenocarcinoma

Lung Adenocarcinoma
Oscar Gerardo Arrieta Rodríguez332 enrolled1 locationNCT06181812
Recruiting
Not Applicable

Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm

Lung Adenocarcinoma
Shanghai Pulmonary Hospital, Shanghai, China690 enrolled14 locationsNCT04937283
Recruiting
Phase 3

Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases

Brain MetastasesLung AdenocarcinomaWhole-Brain Radiotherapy+2 more
Sun Yat-sen University220 enrolled3 locationsNCT07481786
Recruiting
Phase 2

Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer

Stage III Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8Advanced Lung Adenocarcinoma+1 more
Emory University50 enrolled3 locationsNCT06495125
Recruiting
Not Applicable

Low-glucose/High-fat Intake Dietary Regimen as a Tool for Empowering Diagnostic Accuracy of 2-[18F]FDG PET/CT in Lepidic-predominant Growth Lung Adenocarcinoma

Lung AdenocarcinomaLepidic-Predominant Lung Adenocarcinoma
Fondazione del Piemonte per l'Oncologia30 enrolled1 locationNCT07479095
Recruiting
Phase 1

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Breast CancerHead and Neck Squamous Cell CarcinomaMetastatic Malignant Solid Neoplasm+14 more
Anusha Kalbasi18 enrolled3 locationsNCT04119024
Recruiting

Pleural Effusion Biomarkers in Lung Adenocarcinoma Patients

Lung AdenocarcinomaPleural EffusionBiomarkers
Fu Jen Catholic University100 enrolled1 locationNCT07012759
Recruiting
Not Applicable

Engagement of Veterans With Lung Cancer

Lung CarcinomaLung Cancer (Non-Small Cell)Lung Adenocarcinoma+3 more
Palo Alto Veterans Institute for Research194 enrolled1 locationNCT07219251
Recruiting
Phase 1

A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

Advanced Solid TumorMesotheliomaRenal Cancer+3 more
Nuvectis Pharma, Inc.140 enrolled12 locationsNCT05873686
Recruiting
Not Applicable

Partial Tumor Irradiation and Immunotherapy for Unresectable Lung Cancer

Lung AdenocarcinomaBulky TumorsUnresectable Cancer
Karl Landsteiner University of Health Sciences10 enrolled1 locationNCT07423169
Recruiting
Early Phase 1

Testing the Safety of Dapagliflozin Prior to Surgery for the Treatment of Patients With Stage IA Lung Adenocarcinoma

Lung CancerLung AdenocarcinomaStage IA1 Lung Cancer American Joint Committee on Cancer (AJCC) v8+2 more
Jonsson Comprehensive Cancer Center48 enrolled1 locationNCT07235280